This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

SAMR issues rare merger veto, orders 2019 Wuhan Yongtong–Huatai deal unwound

( July 23, 2025, 09:06 GMT | Official Statement) -- MLex Summary: Wuhan Yongtong Pharmaceutical’s completed 2019 acquisition of Shandong Beida Gaoke Huatai Pharmaceutical was blocked by China’s top merger control authority on July 22, marking only the fourth merger prohibition since the country’s Anti-Monopoly Law came into effect in 2008. Notably, it is the first veto involving a transaction below the notification threshold and the first requiring a full rollback to the pre-merger state. The State Administration for Market Regulation found that the deal has harmed competition in China’s papaverine hydrochloride injection market. The decision follows and the statement is attached:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections